scholarly journals Giant cell tumor of bone: Unusual features of a rare tumor

Rare Tumors ◽  
2019 ◽  
Vol 11 ◽  
pp. 203636131987889 ◽  
Author(s):  
Ziyad M Mohaidat ◽  
Hisham Z Al-jamal ◽  
Audai M Bany-Khalaf ◽  
Ahmad M Radaideh ◽  
Ziad A Audat

Giant cell tumor of bone is a benign tumor with an aggressive behavior. Its typical subarticular location and high recurrence risk can be associated with significant morbidity. Although benign, it can rarely metastasize especially to the lungs. Also, it can be multicentric in less than 1% of patients. Late malignant transformation, although rare, can occur with a very poor prognosis. This series reports on these unusual and challenging features and management considerations of giant cell tumor of bone. This retrospective study included review of the medical records of patients with a confirmed histopathological diagnosis of giant cell tumor of bone. A total of 25 patients (16 females and 9 males) with a mean age of 34.5 years were included; 22 had primary tumors, while 3 were referred with recurrent tumors. Pain was the most common presenting symptom. Most patients had grade III tumors. Tumors around the knee were the most common. Multicentric tumors were detected in three patients. Twenty-three patients (20 primary giant cell tumor of bone and 3 with recurrence) received treatment. Most patients (15/23) were treated with intralesional curettage with or without adjuvants. Seven patients had wide excision. Recurrence was seen in 45% (9/20) of primary giant cell tumor of bone especially with difficult anatomical locations. Most recurrences occurred more than 4 years after treatment. Pulmonary nodules were detected in four patients; two of them showed resolution during follow-up. One patient developed secondary sarcoma transformation with a fatal outcome. Giant cell tumor of bone was more common in females. Long bones were more affected, especially around the knee. Intralesional curettage was the most frequently used treatment. Recurrence was associated with inadequate tumor resection (especially in difficult anatomical location), younger age, male gender, and advanced local tumor grade. Denosumab can be used in the treatment of pulmonary metastasis, multicentric and recurrent giant cell tumor of bone. Due to late recurrence and malignant transformation, a prolonged follow-up is warranted.

Author(s):  
Rahul Bharadwaj ◽  
Vipin Sharma ◽  
Narinder Singh ◽  
Narinder Singh

<p>Giant cell tumour forms 4% of all primary tumors. GCT distal radius is very rare. Current study presents a case of a 27 year female who was managed by wide excision and reconstruction with ipsilateral fibula. At one year follow up, patient had excellent range of motion at wrist joint and hand.</p>


SICOT-J ◽  
2015 ◽  
Vol 1 ◽  
pp. 18 ◽  
Author(s):  
Serda Duman ◽  
Hakan Sofu ◽  
Yalkin Camurcu ◽  
Sarper Gursu ◽  
Ramadan Oke

2013 ◽  
Vol 7 (1) ◽  
pp. 103-108 ◽  
Author(s):  
Theresa J.C Pazionis ◽  
Hussain Alradwan ◽  
Benjamin M Deheshi ◽  
Robert Turcotte ◽  
Forough Farrokhyar ◽  
...  

Introduction: Surgical management of Giant Cell Tumor of Bone of the distal radius (GCTDR) remains controversial due to risk of local recurrence (LR) offset by functional limitations which result from en-bloc resection. This study aims to determine the oncologic and functional outcomes of wide excision (WE) vs intralesional curettage (IC) of GCTDR. Methods: A complete search of the applicable literature was done. Included studies reported on patients from the same cohort who were surgically treated for GCTDR with WE or IC. Two reviewers independently assessed all papers. The primary outcome measure was LR. Results: One-hundred-forty-one patients from six studies were included: 60 treated with WE, and 81 with IC. Five WE patients (8%) suffered LR whereas 25 IC patients (31%) did. The odds of LR were three times less in the WE group vs the IC group. MSTS1993 scores, where available, were on average 'good' with WE and 'excellent' with IC. Conclusions: Within statistical limitations the data support an attempt, where feasible, at wrist joint preservation and superior function with IC. Intralesional curettage is reasonable when the functional benefit outweighs the risk of recurrence as is the case in many cases of GCT of the distal radius.


1998 ◽  
Vol 28 (5) ◽  
pp. 323-328 ◽  
Author(s):  
Y. Oda ◽  
H. Miura ◽  
M. Tsuneyoshi ◽  
Y. Iwamoto

2020 ◽  
Vol 4 (1) ◽  
pp. 64-67
Author(s):  
Sushil Adhikari ◽  
Arun Sigdel ◽  
Rajesh Kumar Sah ◽  
Luna Devkota

Giant cell tumour (GCT) is histopathologically benign tumor of long bone particularly in distal femur and the proximal tibia. It commonly occurs in adults of age 20-40 years but rare in children. GCT is considered to be locally aggressive tumor and tendency of recurrence is higher even after surgery. The clinical features are nonspecific, the principle symptoms are pain, swelling and limiting adjacent joint movements. Diagnosis is based on the radiographic appearance and histopathological findings .In our case X-ray showed ill defined lytic lesion on proximal fibula with cortical thinning and MRI finding revealed expansile lyticlesion in meta-epiphysis of right fibula 16×16×28mm adjacent to growth plate with fluid level. The sclerotic rim appears hypo intense on T1 & hyper intense on T2. Core needle biopsy showed giant cell tumor on proximal fibula. Considering the risk of recurrence wide local excision was done. Management of GCT of proximal fibula in young patient is critical for preventing recurrence and enhancing functional outcomes by saving adjacent anatomical structure. No evidence of local recurrence and metastasis was found in 24 months of follow up.


Author(s):  
JORGE ESQUICHE LEÓN ◽  
LUCIANA YAMAMOTO DE ALMEIDA ◽  
MARISOL MARTÍNEZ MARTÍNEZ ◽  
FERNANDA DOS SANTOS MOREIRA ◽  
ALÍCIA RUMAYOR PIÑA ◽  
...  

Hand Surgery ◽  
2012 ◽  
Vol 17 (01) ◽  
pp. 125-127
Author(s):  
J. Terrence Jose Jerome ◽  
Kumar Venkatesan ◽  
Amarnath G ◽  
Usha Rani ◽  
Rohini Sridhar

We report a 75-year-old man who presented with a painless friable mass in the index finger pulp mimicking pyogenic granuloma. Complete excision of the mass was done. The radiological and the histopathological findings suggested giant cell tumor of the tendon sheath. The patient had no recurrence at the end of a two-year follow-up. This unusual clinical presentation of the giant cell tumor of the tendon sheath was our study base and adds up to its variant presentation in the literature.


2007 ◽  
Vol 62 (3) ◽  
pp. 89-93 ◽  
Author(s):  
Eric J. Heffernan ◽  
Paul J. O'Sullivan ◽  
Manoochehr Adibeig ◽  
Luck J. Louis ◽  
Anthony G. Ryan ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-6
Author(s):  
Ahmed Hamed Kassem Abdelaal ◽  
Norio Yamamoto ◽  
Katsuhiro Hayashi ◽  
Akihiko Takeuchi ◽  
Shinji Miwa ◽  
...  

Introduction. The main indication for knee arthrodesis in tumor surgery is a tumor that requires an extensive resection in which the joint surface cannot be preserved. We report a patient that had knee desarthrodesis 41 years after giant cell tumor resection followed by a knee arthrodesis. This is the longest reported follow-up after desarthrodesis and conversion to total knee arthroplasty (TKA), almost ten years.Case Report. A 71-year-old man with a distal femoral giant cell tumor had undergone a resection of the distal femur and knee arthrodesis using Kuntscher nail in 1962. In July 2003 he experienced gradually increasing pain of his left knee. We performed a desarthrodesis and conversion to TKA in 2005. The postoperative period passed uneventfully as his pain and gait improved, with gradually increasing range of motion (ROM) and no infection. He now walks independently, with no brace or contractures.Conclusion. Desarthrodesis of the knee joint and conversion to TKA are a difficult surgical choice with a high complication risk. However, our patient’s life style has improved, he has no pain, and he can ascend and descend stairs more easily. The surgeon has to be very meticulous in selecting a patient for knee arthrodesis and counseling them to realize that their expectations may not be achievable.


Sign in / Sign up

Export Citation Format

Share Document